DEVELOPMENT OF A DE NOVO MODEL TO ASSESS THE COST-EFFECTIVENESS OF A NEW TREATMENT OPTION FOR PATIENTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)

被引：0
|
作者：
Davies, N. [1 ]
Dickinson, O. [1 ]
Downward, L. [2 ]
Pitcher, D. [2 ]
Gale, D. [3 ]
Ioannou, P. [1 ]
Kipentzoglou, K. [4 ]
Crabtree, M. [5 ]
机构：
[1] Mtech Access Ltd, Bicester, England
[2] UK Renal Registry, Bristol, BST, England
[3] UCL, London, England
[4] Britannia Pharmaceut Ltd, Reading, England
[5] STADA, Bad Vilbel, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE119
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF UPADACITINIB AS A TREATMENT OPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN KINGDOM OF SAUDI ARABIA
    Alabdulkarim, H.
    Almodaimegh, H.
    Abu Esba, L. C.
    Sharma, Y.
    Attar, S.
    Hussain, W.
    Alhomood, I
    Al-Omari, B. A.
    Mohamed, O.
    Alsaqa'aby, M.
    Roshdy, A.
    Anwar, A.
    Hamad, T.
    Alzahrani, Z.
    VALUE IN HEALTH, 2022, 25 (07) : S407 - S407
  • [22] Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia
    Al-Abdulkarim, Hana
    Sharma, Yuvraj
    Attar, Suzan M.
    Husain, Waleed
    Al-Homood, Ibrahim
    Al Omari, Bedor
    Mohamed, Omneya
    Alsaqa'aby, Mai
    Jaheen, Ahmed M.
    Anwar, Ali
    Hamad, Tharwat M.
    Alzahrani, Zeyad
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 134 - 144
  • [23] The cost-effectiveness of primary therapist model for the management of patients with rheumatoid arthritis.
    Li, LC
    Maetzel, A
    Davis, AM
    Lineker, S
    Bombardier, C
    Coyte, P
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S508 - S509
  • [24] Cost-Effectiveness of an Improved Care Model for Patients with Anxiety Disorders in Primary Care
    Koenig, Hans-Helmut
    Born, Anja
    Heider, Dirk
    Matschinger, Herbert
    Heinrich, Sven
    Riedel-Heller, Steffi G.
    Surall, Daniel
    Angermeyer, Mathias C.
    Roick, Christiane
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S26 - S26
  • [25] A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada
    Beauchemin, C.
    Letarte, N.
    Mathurin, K.
    Yelle, L.
    Lachaine, J.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (06) : 619 - 629
  • [26] Probabilistic markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries
    Oostenbrink, JB
    Rutten-van Mölken, MPMH
    Monz, BU
    FitzGerald, JM
    VALUE IN HEALTH, 2005, 8 (01) : 32 - 46
  • [27] EVALUATION OF COST-EFFECTIVENESS OF SELECTIVE LASER TRABECULOPLASTY AS A FIRST OPTION IN PRIMARY OPEN ANGLE GLAUCOMA TREATMENT IN COLOMBIA
    Bernal, M. M.
    Organista, J.
    Rico, A.
    Romero, M.
    Barrero, J. R.
    VALUE IN HEALTH, 2013, 16 (07) : A696 - A696
  • [28] A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany
    Flachenecker, Peter
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (03) : 15 - 19
  • [29] Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis
    Dai, Pinyuan
    Xie, Weihua
    Yu, Xiaojin
    Sun, Jinfang
    Wang, Shiyuan
    Kawuki, Joseph
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 94
  • [30] A methodological approach to assess cost data in the context of a decision analytic model to evaluate the cost-effectiveness of the treatment of the metabolic syndrome
    Aidelsburger, P
    Wasem, J
    VALUE IN HEALTH, 2005, 8 (06) : A68 - A68
12345